Fig. 4

Line charts showing the variation of overall resistance rates in tested isolates including E. coli (A), Klebsiella spp. (B), Enterobacter spp. (C), Proteus spp. (D), Pseudomonas spp. (E), Acinetobacter spp. (F), CoPS (G), CoNS (H), E. faecium (I), E. faecalis (J), and Streptococcus spp. (K) from 2018 to 2021. Abbreviations: ampicillin (AMP), amoxicillin-clavulanate (AMC), ceftriaxone (CRO), cefquinome (CEQ), meropenem (MEM), doxycycline (DOX), tigecycline (TGC), gentamicin (GEN), amikacin (AMK), colistin (COL), florfenicol (FFC), levofloxacin (LVX), enrofloxacin (ENR), trimethoprim-sulfamethoxazole (SXT), cephalexin (LEX), ceftiofur (CEF), oxacillin (OXA), azithromycin (AZM), daptomycin (DAP), fusidic acid (FAD), linezolid (LZD), rifampin (RIF), vancomycin (VAN), coagulase-positive Staphylococcus (CoPS), coagulase-negative Staphylococcus (CoNS). Asterisks represent the statistical significance of the variation trends in the resistance rates of the corresponding antimicrobial agents from 2018 to 2021. p < 0.05 (*) and p < 0.01 (**) are considered as statistically significant. The breakpoints for S. aureus from bovine mastitis to ceftiofur and for S. pseudintermedius from dogs to doxycycline were used to determine the resistance of Staphylococcus spp. from dogs and cats in this study. As florfenicol breakpoints for Staphylococcus spp., Enterococcus spp. and Streptococcus spp. from dogs and cats have not been established, the florfenicol breakpoints approved for Streptococcus suis from pigs were used to determine florfenicol resistance in the aforementioned pathogens this study